Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: Higher baseline levels of immunoglobulin M (IgM) anti-phosphorylcholine (anti-PC) autoantibodies in early rheumatoid arthritis (RA) showed benefits in the reduction of cardiovascular risk in younger patients, men, and those at risk for cardiovascular event.

Major finding: Baseline IgM anti-PC autoantibody level above vs below median was associated with lower risk of cardiovascular outcome in patients below 55 years of age at inclusion (adjusted hazard ratio [aHR], 0.360; P = .032), male patients (aHR, 0.558; P = .034), those with a body mass index greater than 30 kg/m² (aHR, 0.235; P = .026), and those who did not achieve Disease Activity Score for 28 joints remission at 1 year (aHR, 0.592; P = .021).

Study details: Findings are from an analysis of 653 patients with early RA without prevalent cardiovascular disease from the prospective, observational BARFOT cohort.

Disclosures: The Swedish Rheumatism Association, the King Gustav V 80 year’s Foundation, and the Swedish Heart-Lung Foundation funded this research. J Frostegård declared being a registered patent holder for anti-PC.

Source: Ajeganova S et al. Arthritis Res Ther. 2021 Jul 27. doi: 10.1186/s13075-021-02581-0.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: In real medical practice, tofacitinib and baricitinib demonstrated comparable efficacies and similar safety profiles in patients with rheumatoid arthritis (RA); however, predictive factors contributing to their treatment responses were different.

Major finding: At 24 weeks, clinical response (adjusted mean difference, −0.04; 95% confidence interval, −0.35 to 0.28) and adverse events (P = .866) were not significantly different between the 2 groups. Factors independently associated with the achievement of disease activity score-low disease activity were concomitant oral steroid use (odds ratio [OR], 0.470) in the tofacitinib group and the number of previous use of biological and/or targeted synthetic disease-modifying antirheumatic drugs (OR, 0.700) in the baricitinib group (both P < .05).

Study details: Findings are from the analysis of a real-world cohort of 242 patients with RA who were treated with tofacitinib (n=161) between August 2013 and October 2019 or baricitinib (n=81) between January 2018 and February 2020.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Iwamoto N et al. Arthritis Res Ther. 2021 Jul 23. doi: 10.1186/s13075-021-02582-z.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Patients with rheumatoid arthritis (RA) currently using low-dose oral glucocorticoid (7.5 mg or lower of prednisolone equivalent dose/day) were at a 59% increased risk of sustaining clinical vertebral fracture compared with past users.

Major finding: Although the overall risk for osteoporotic fractures was not different between past and current users of low-dose oral glucocorticoids (adjusted hazard ratio [aHR], 1.14; 95% confidence interval [CI], 0.98-1.33), the risk for clinical vertebral fracture was significantly higher with current use (aHR, 1.59; 95% CI, 1.11-2.29).

Study details: This was a retrospective cohort study of 15,123 adults aged 50 years or older from the Clinical Practice Research Datalink who were diagnosed with RA between 1997 and 2017.

Disclosures: No specific funding was received for this study. AM Burden and JP van den Bergh reported receiving grants and lectures/advisory board meetings fees from various sources. FD Vries supervised 3 PhD students who were employed with F. Hoffmann La Roche Ltd. All the other authors declared no conflict of interests.

Source: Abtahi S et al. Rheumatology (Oxford). 2021 Jul 13. doi: 10.1093/rheumatology/keab548.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: Olokizumab significantly improved signs and symptoms of rheumatoid arthritis (RA) in patients with inadequate response to methotrexate and was reasonably well tolerated over a period of 24 weeks.

Major finding: At 12 weeks, the proportion of patients who achieved American College of Rheumatology 20% response was significantly higher with olokizumab every 2 (63.6%) and 4 (70.4%) weeks vs placebo (25.9%; both P < .0001). Most treatment-emergent adverse events were mild to moderate.

Study details: Findings are from CREDO 1, a phase 3 trial of 428 patients with active RA despite treatment with methotrexate who were randomly assigned to receive subcutaneous olokizumab 64 mg once every 2 or 4 weeks or placebo with continuation of background methotrexate.

Disclosures: This study was funded by CJSC R-Pharm. E Korneva and M Samsonov reported being employees of R-Pharm. Some of the authors declared receiving consulting fees and/or research grants from, being on speakers’ bureau for, being consultant and/or employee of, and/or holding stocks for various sources.

Source: Nasonov E et al. Ann Rheum Dis. 2021 Aug 3. doi: 10.1136/annrheumdis-2021-219876.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases. The OS was similar regardless of the BRI type used.

Major finding: The median follow-up was 23.5 months. Concomitant use of BRIs was reported in 29.0% of patients. BRI use was associated with OS improvement (31.8 months vs 23.0 months; hazard ratio [HR], 0.65; P less than .001) and shorter time to the first skeletal-related event (32.4 months vs 42.7 months; HR, 1.27; P = .04). Both denosumab and zoledronic acid were associated with similar OS (P = .79).

Study details: A retrospective study of 745 consecutive patients with metastatic CRPC and bone metastases who received abiraterone acetate plus prednisone between 2013 and 2016.

Disclosures: No funding source was reported. The authors received grants, personal fees, travel expenses, and research funding from and/or owned stocks in pharmaceutical companies outside the submitted work.

Source: Francini E et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.16536.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: In patients with localized prostate cancer, the use of phosphodiesterase (PDE)-5 inhibitors improve survival.

Major finding: The patients who received PDE-5 inhibitors vs those who did not showed a significant improvement in biochemical recurrence-free (BCRF) survival (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.34-0.56) and overall survival (OS; HR, 0.65; 95% CI, 0.45-0.94) at 10 years. In PDE-5 inhibitors users vs nonusers, BCRF survival was 93.2% vs 85.3% and OS was 95.8% vs 94.5%.

Study details: A retrospective cohort study of 3,100 patients with prostate cancer who underwent radical prostatectomy between 2003 and 2015; 1,372 patients received PDE-5 inhibitors.

Disclosures: The study was supported by National Cancer Institute. The authors declared no conflict of interests.

Source: Danley KT et al. Urol Oncol. 2021 Jul 18. doi: 10.1016/j.urolonc.2021.05.031.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.

Key clinical point: Positive prostate-specific membrane antigen positron emission tomography (PSMA PET) findings prior to salvage radiotherapy (SRT) are associated with worse metastasis-free survival (MFS) in patients with recurrent prostate cancer.

Major finding: In 155 patients who underwent PSMA PET prior to SRT, 31.6% had positive PSMA PET. After propensity score matching, 5-year MFS was significantly lower in patients with “positive PSMA PET” vs those who did not undergo PSMA PET (48.5% vs 92.3%; P < .001). Positive PSMA PET imaging was associated with worse MFS compared with “no PSMA PET” (hazard ratio, 13.8; P < .001).

Study design: A retrospective study of 1,599 patients with recurrent prostate cancer who received salvage radiotherapy after biochemical recurrence.

Disclosures: The study received no funding. The authors declared no conflict of interests.

Source: Wenzel M et al. Urol Oncol. 2021 Jul 31. doi: 10.1016/j.urolonc.2021.06.008.

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.

Key clinical point: In patients with Gleason grade 3+4 prostate cancer treated with brachytherapy, high prostate-specific antigen (PSA) levels are associated with an elevated risk for prostate cancer-specific mortality (PCSM).

Major finding: The median follow-up was 7.8 years. The PSA levels of 10.1-20.0 ng/mL vs 4.0-10.0 ng/mL were associated with higher PCSM in patients who received brachytherapy alone (adjusted hazard ratio [aHR], 5.55; P < .001) and those who received brachytherapy with androgen deprivation treatment (ADT; aHR, 4.17; P = .02).

Study details: A retrospective study of 1,920 patients with Gleason grade 3+4 prostate cancer who received brachytherapy with or without ADT.

Disclosures: No funding source was reported. The authors did not report any conflict of interests.

Source: Yang DD et al. Urol Oncol. 2021 Jul 24. doi: 10.1016/j.urolonc.2021.06.022.

Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.

Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.

Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.

Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.

Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.

Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.

Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.

Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.

Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.

Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.

Key clinical point: Nomograms to predict survival and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177 prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment have been developed and externally validated.

Major finding: The median follow-up was 21.5 months. The concordance index of the overall survival model was 0.71 and PSA-progression-free survival model was 0.70. The model for PSA decline of 50% or more had a sensitivity of 94%, negative predictive value of 89%, and specificity of 38%.

Study details: Nomograms for predicting outcomes after Lu-PSMA treatment were developed (n=196) and validated (n=74) using clinical trial and real-world data of patients with late-stage mCRPC.

Disclosures: The study was supported by Prostate Cancer Foundation. The authors declared consulting, personal fees, travel fees, grants, honoraria, nonfinancial support, and patents outside this work. Dr. J Czernin reported being a founder and board member of and holding equity in Sofie Biosciences and Trethera Therapeutics.

Source: Gafita A et al. Lancet Oncol. 2021 Jul 8. doi: 10.1016/S1470-2045(21)00274-6.

Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.

Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.

Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.

Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.

Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.

Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.

Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.

Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.

Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.

Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.

Key clinical point: Talazoparib shows antitumor response in heavily pretreated patients with metastatic, castration-resistant prostate cancer (CRPC) with alterations in DNA damage repair (DDR) genes.

Major finding: The median follow-up was 16.4 months. The confirmed objective response rate (ORR) was 29.8%. The ORR was 46% in patients with BRCA2 alterations and 50% in those with BRCA1 alterations. Grade 3-4 adverse event rate was 48%; anemia, thrombocytopenia, and neutropenia were most common.

Study details: A multicenter, phase 2 TALAPRO-1 trial of 127 heavily pretreated patients with metastatic, CRPC with alterations in DDR genes who received talazoparib; 104 patients had measurable soft tissue disease.

Disclosures: This study was funded by Pfizer. The authors received grants/funding, consulting fees, travel/accommodation expenses, and/or honoraria from and/or reported employment and/or stock ownership in companies. Dr. JS de Bono also reported patent ownership.

Source: de Bono JS et al. Lancet Oncol. 2021 Aug 10. doi: 10.1016/ S1470-2045(21)00376-4.